CSPC Pharmaceutical Group Limited
1093
Hisse Senetlerindeki Sıralama
#1743
CSPC Pharmaceutical Group Limited, primarily an investment holding entity, is... CSPC Pharmaceutical Group Limited, primarily an investment holding entity, is dedicated to the development, production, and distribution of pharmaceutical goods. Its operations span the globe, with a significant presence in the People's Republic of China, across Asia, in the Americas, and throughout Europe. The company structures its business activities into three main divisions: Finished Drugs, Bulk Products, and Functional Food and Other ventures. The company's extensive portfolio of finished drugs encompasses treatments for a wide range of conditions. Key offerings include NBP (available as soft capsules and injections) for acute ischemic stroke, and Oulaining (capsules and injections) addressing mild to moderate memory and cognitive impairments. For neurological disorders, Enxi targets adult idiopathic Parkinson's disease. In oncology, Duomeisu treats lymphoma, multiple myeloma, ovarian and breast cancers, alongside other malignant tumors, while Jinyouli aids in preventing chemotherapy-induced leucopenia and infections, and Keaili is prescribed for breast cancer. Further therapeutic areas covered by CSPC include various infections, with products such as Shuluoke, Nuomoling, Weihong, and Xinweihong. Cardiovascular health is addressed by Xuanning for hypertension and Encun to avert atherosclerotic thrombosis events. Qixiao provides relief for upper respiratory tract infections, and diabetes management is supported by Linmeixin and Shuanglexin. Bone health solutions include Gubang and Gubangjia for postmenopausal osteoporosis. Additionally, Gaoshunsong offers relief for a broad spectrum of inflammatory and pain-related conditions, including arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursitis, tenosynovitis, acute gout, dysmenorrhea, toothache, postoperative pain, lower back pain, sprains, strains, and other soft tissue injuries. Other notable products include Debixin for various types of ulcers and Qimaite for acute and chronic pain management. Beyond finished pharmaceuticals, CSPC also supplies active pharmaceutical ingredients (APIs) like antibiotics, vitamin C, and caffeine. The company further diversifies into functional foods, glucose products, and provides healthcare services. Originally established in 1992, the company initially operated under the name China Pharmaceutical Group Limited before adopting its current designation, CSPC Pharmaceutical Group Limited, in March 2013. Its primary corporate office is situated in Shijiazhuang, within the People's Republic of China.
Hisse Fiyatı
$1.06
Piyasa Değeri
$12.14B
Değişim (1 gün)
-3.97%
Değişim (1 yıl)
-2.20%
Ülke
CN
Ticaret CSPC Pharmaceutical Group Limited (1093)
Kategori
Healthcare
CSPC Pharmaceutical Group Limited (1093) için kazanç
2026 itibarıyla kazanç TTM: 0
CSPC Pharmaceutical Group Limited şirketinin en son finansal raporlarına göre, mevcut kazancı 0'dir. 2026 yılında şirket 0 kazanç elde etti, bu 2026 yılındaki 0 kazanca göre önceki yıla eşit. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
CSPC Pharmaceutical Group Limited için kazanç geçmişi 2003 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2025 | $669.44M | -13.99% |
| 2024 | $778.29M | -25.49% |
| 2023 | $1.04B | -6.94% |
| 2022 | $1.12B | 5.94% |
| 2021 | $1.06B | 14.55% |
| 2020 | $924.92M | 58.26% |
| 2019 | $584.45M | 15.90% |
| 2018 | $504.29M | 34.77% |
| 2017 | $374.19M | 22.91% |
| 2016 | $304.45M | 33.52% |
| 2015 | $228.02M | 38.40% |
| 2014 | $164.75M | 2.39% |
| 2013 | $160.90M | -32.67% |
| 2012 | $238.98M | 442.91% |
| 2011 | $44.02M | -58.20% |
| 2010 | $105.30M | -17.58% |
| 2009 | $127.76M | -2.08% |
| 2008 | $130.48M | 107.89% |
| 2007 | $62.76M | 30,500.84% |
| 2006 | $205.10K | -98.97% |
| 2005 | $19.98M | -41.50% |
| 2004 | $34.15M | -57.89% |
| 2003 | $81.11M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $33.60B | - |
US
|
|
| $17.74B | - |
US
|
|
| $8.70B | - |
US
|
|
| $5.95B | - |
US
|
|
| $21.39B | - |
CH
|
